Sunday, 4 October 2026European Markets

KID And CATANA GROUP Have A High Dividend Yield And Return On Equity In The Consumer Cyclical Sector.

Loading stream...

(vianews) - kid (kid.ol) is among this list of stock assets with the highest dividend rate and return on equity on the consumer cyclical sector.

financial asset price forward dividend yield return on equity
kid (kid.ol) kr150.00 6.11% 24.25%
catana group (catg.pa) €4.70 3.1% 28.04%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. kid (kid.ol)

6.11% forward dividend yield and 24.25% return on equity

kid asa, together with its subsidiaries, operates as a home textile retailer in norway, sweden, finland, and estonia. it designs, sources, markets, and sells a range of home and interior products, including textiles, curtains, bed linens, home accessories, decorations, furniture, and other interior products through retail stores and online platforms. the company provides its products under the kid, hemtex, dekosol, nordun, and premium collection brands. it also offers logistics services. the company was formerly known as nordisk tekstil holding as and changed its name to kid asa. kid asa was founded in 1937 and is headquartered in lier, norway.

earnings per share

as for profitability, kid has a trailing twelve months eps of kr7.72.

pe ratio

kid has a trailing twelve months price to earnings ratio of 19.43. meaning, the purchaser of the share is investing kr19.43 for every norwegian krone of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 24.25%.

volatility

kid's last week, last month's, and last quarter's current intraday variation average was 0.50%, 0.35%, and 1.41%.

kid's highest amplitude of average volatility was 1.71% (last week), 1.35% (last month), and 1.41% (last quarter).

yearly top and bottom value

kid's stock is valued at kr150.00 at 02:30 est, under its 52-week high of kr152.60 and way above its 52-week low of kr71.40.

more news about kid.

2. catana group (catg.pa)

3.1% forward dividend yield and 28.04% return on equity

sa catana group manufactures and catamarans and related services in france and internationally. the company markets its products under the catana, bali, and port pin roland brand names. sa catana group was incorporated in 1993 and is headquartered in canet-en-roussillon, france.

earnings per share

as for profitability, catana group has a trailing twelve months eps of €0.63.

pe ratio

catana group has a trailing twelve months price to earnings ratio of 7.46. meaning, the purchaser of the share is investing €7.46 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 28.04%.

volatility

catana group's last week, last month's, and last quarter's current intraday variation average was a negative 0.69%, a positive 0.17%, and a positive 1.78%.

catana group's highest amplitude of average volatility was 0.85% (last week), 1.69% (last month), and 1.78% (last quarter).

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, catana group's stock is considered to be overbought (>=80).

revenue growth

year-on-year quarterly revenue growth grew by 44.8%, now sitting on 207.33m for the twelve trailing months.

more news about catana group.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com